ValiRx Plc’s (VAL) Corporate Rating Reaffirmed at Northland Securities

Northland Securities reiterated their corporate rating on shares of ValiRx Plc (LON:VAL) in a report issued on Thursday morning.

Separately, Beaufort Securities reiterated a speculative buy rating on shares of ValiRx Plc in a research report on Friday, July 8th.

Shares of ValiRx Plc (LON:VAL) traded up 4.28% during mid-day trading on Thursday, reaching GBX 7.56. 649,847 shares of the company’s stock were exchanged. The company’s market cap is GBX 3.96 million. ValiRx Plc has a 52-week low of GBX 5.75 and a 52-week high of GBX 28.01. The company’s 50-day moving average price is GBX 7.56 and its 200 day moving average price is GBX 8.56.

About ValiRx Plc

ValiRx plc is a biopharmaceutical company. The principal activity of the Company is the development of oncology therapeutics and companion diagnostics. It focuses on the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. It operates in two business segments: drug development and the sale of self-test drug kits.

Receive News & Ratings for ValiRx Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ValiRx Plc and related companies with's FREE daily email newsletter.

Leave a Reply

© 2006-2016 Mideast Time.